comparemela.com

Latest Breaking News On - பகிரப்பட்டது திறன் - Page 1 : comparemela.com

Investegate |CompuGroup Medical SE & Co Announcements | CompuGroup Medical SE & Co: Universitätsklinik Hamburg-Eppendorf (UKE) decides for a future with CGM CLINICAL

DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Miscellaneous Universitätsklinik Hamburg-Eppendorf (UKE) decides for a future with CGM CLINICAL 15.04.2021 / 09:05 The issuer is solely responsible for the content of this announcement. Koblenz. CompuGroup Medical (CGM), one of the world s leading providers of e-health solutions, announced today that the medical center Universitätsklinik Hamburg-Eppendorf (UKE), one of Europe s leading university clinics, selected the CGM CLINICAL hospital information system as the core enterprise-wide electronic health record (EHR) system. For more than a decade, UKE has been a pioneer in digitization of healthcare and is now taking the next step by choosing an innovative partner. Using cutting-edge features will further propel UKE s experience in case as part of an integrated patient journey.

Universitätsklinik Hamburg-Eppendorf (UKE) decides for a future with CGM CLINICAL

Universitätsklinik Hamburg-Eppendorf (UKE) decides for a future with CGM CLINICAL
dgap.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dgap.de Daily Mail and Mail on Sunday newspapers.

Evotec AG: Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure

Evotec AG: Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure RISK-REWARD-SHARING PARTNERSHIP LEVERAGES COMPLEMENTARY PLATFORMS HAMBURG, GERMANY / ACCESSWIRE / February 4, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has entered into a multi-year partnership with the Medical Center Hamburg-Eppendorf ( UKE ) for the development of a highly innovative first-in-class cell therapy approach for the treatment of heart failure. Under the terms of the partnership, Evotec and UKE will leverage their complementary strengths for the development of a new cell therapy approach using Engineered Heart Tissue for the treatment of heart failure. Heart failure is frequently associated with ischemic heart disease and often comes with a poor prognosis. Mortality is comparable to that of the most common cancers, with

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.